Key Takeaway: Nurix is committed to developing innovative therapies targeting cancer and autoimmune diseases. Their approach involves a multi-modal portfolio that includes both wholly owned and partnered assets. The company is particularly focused on protein degradation as a promising avenue for treatment.
Price reaction · baseline $8.37 (2024-01-29 close) · hit pre-market · 1 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
-4.5%
Market Sentiment Analysis
POSITIVE FACTORS
Nurix is advancing a multi-modal portfolio of therapies.
The focus on protein degradation may lead to breakthrough treatments.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.